PETcision Co., Ltd.
Update：2026/11/10
Industries
Main Industry
Health Care
Main Product/Service
The novel canine cancer genetic testing service, "OncoDetect", enables minimally invasive, highly accurate cancer detection using only a blood sample. The product utilizes the most advanced liquid biopsy and next-generation sequencing (NGS) technologies from human medicine, combined with AI analysis models, to detect up to 20 common canine cancers. This assists veterinarians in early intervention and precise treatment, significantly improving clinical efficiency and prognostic outcomes.
The content above was translated by Ai
Founded Year
2023
Unified Business No.
94095802
Status
Active
Number of Employees
0
Total Paid-in
Capital
10,296,209 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
PETcision Co., Ltd. is an innovative biotechnology company with pet cancer molecular diagnostics and a precision medicine big data platform at its core. Our flagship product, "An-Shi-You," is a novel canine cancer genetic testing service that provides a safe, accurate, and convenient cancer detection method. Requiring only a blood draw, it can simultaneously detect 20 different types of canine cancers, assisting clinical veterinarians in making more precise diagnostic and treatment decisions. "An-Shi-You" has currently been introduced to more than a hundred animal hospitals across Taiwan, and clinical validation collaborations have been established with leading domestic academic and medical institutions.
The content above was translated by Ai
